Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clivatuzumab
- Development stage
- Discontinued
- Lead developer
- Gilead Sciences
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Clivatuzumab (PAM4) is a humanized monoclonal antibody that targets a specific epitope of Mucin-1 (MUC1), a glycoprotein that is highly expressed in pancreatic ductal adenocarcinoma but not in normal pancreatic tissue or pancreatitis. Developed by Immunomedics, the antibody was primarily developed as a radiopharmaceutical conjugate, clivatuzumab tetraxetan (IMMU-107), which is labeled with Yttrium-90 (90Y) for the treatment of advanced pancreatic cancer. Although it showed promise in early-phase trials and reached Phase 3 clinical development (the PANCRIT-1 trial), the program was discontinued after the trial failed to demonstrate a significant improvement in overall survival.
- Other names
- clivatuzumab tetraxetan90Y-clivatuzumab tetraxetanhumanized PAM4anti-MUC1 monoclonal antibody PAM4anti-MUC-1 monoclonal antibody PAM4anti-MUC 1 monoclonal antibody PAM4
02
Targets
MUC1 (Mucin-1 Antigen)MUC5AC (Mucin-5AC)
Beyond the preview
Go deeper on clivatuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clivatuzumab.